Orthocell (ASX:OCC) Achieves Early Sales of Nerve Repair Product in Singapore

2 min read | December 12, 2024 03:20 PM AEDT | By Team Kalkine Media

Google News:

Orthocell (ASX:OCC) Achieves Early Sales of Nerve Repair Product in Singapore — Image source: shutterstock

Recent News

Could ASX Growth Stocks Be Set for the Next Market Shift?

Woolworths Climbs While Coles Skirts 52-Week Lows: The Supermarket Spl...

Retail Under Pressure: Why ASX Retail Stocks Face a Tougher Road Ahead

ASX Growth Stocks: Hidden Catalysts and Market Signals

Make Kalkine Media
My Trusted Source

Highlights

Orthocell (OCC) marks its first sales of Remplir in Singapore.

Remplir supports nerve healing with its collagen-based design.

Early success achieved ahead of its anticipated 2025 launch.

Orthocell (ASX:OCC), a leading regenerative medicine company, has successfully secured its first sales of Remplir, a peripheral nerve repair product, in Singapore. This milestone comes months ahead of a broader launch initially planned for the first quarter of 2025.

Remplir is designed to aid in nerve regeneration using a specialized collagen-based material. The product provides a protective environment for damaged nerves, acting as a conduit to shield nerves from external pressures while fostering a stable and compression-free healing process. The technology represents a significant step forward in enhancing outcomes for patients requiring nerve repair.

The initial sales were secured through Device Technologies Asia, a regional distributor well-versed in medical technology. Device Technologies Asia has already developed key relationships with specialists in the field, including plastic reconstructive and orthopedic surgeons operating at premier surgical centers in Singapore. These collaborations have paved the way for Remplir's entry into the market, just two months after receiving approval from Singapore's Health Sciences Authority in October 2024.

Orthocell’s decision to accelerate its entry into the Singapore market demonstrates the company’s ability to adapt to evolving healthcare demands while maintaining focus on delivering innovative solutions. The early sales underscore the potential of Remplir to become an essential tool for surgeons specializing in nerve repair and regeneration.

Looking ahead, Orthocell anticipates steady growth in sales and increased adoption by surgeons throughout the coming year. With the Singapore market as a launchpad, the company is poised to expand its global footprint for Remplir, positioning the product as a transformative solution in peripheral nerve repair.

This achievement not only highlights Orthocell’s commitment to innovation but also emphasizes its strategic approach to global market penetration. The introduction of Remplir in Singapore signifies an exciting chapter for Orthocell and the broader field of regenerative medicine.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.